You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory/relapse

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)

Recruiting
  • Refractory/Relapse Acute Myeloid Leukemia
  • Kunming, Yunnan, China
    Department of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023

Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors With Lung Metastases Trial in Fukuoka (Biological)

Recruiting
  • Refractory/Relapse Neuroblastoma
  • Pediatric Solid Tumors With Lung Metastases
  • Biological
  • Fukuoka, Japan
    Kyushu University Hospital
Nov 7, 2022

Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Diffuse Scleroderma Trial in Shanghai (BRL-301)

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • +5 more
  • BRL-301
  • Shanghai, Shanghai, China
    Shanghai ChangZheng hospital
May 7, 2023

Multiple Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jan 5, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Oct 30, 2023

    Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

    Recruiting
    • Acute Myeloid Leukemia Refractory
    • Acute Myeloid Leukemia, in Relapse
    • anti Tim-3/CD123 CAR-T cell therapy
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 4, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • (no location specified)
    Nov 9, 2023

    Advanced Pancreatic Cancer Trial in Nanjing (Adoptive TIL-TCM transfer therapy)

    Recruiting
    • Advanced Pancreatic Cancer
    • Adoptive TIL-TCM transfer therapy
    • Nanjing, Jiangsu, China
      Jinling Hospital
    Jun 29, 2022

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

    Recruiting
    • Relapse/Refractory Multiple Myeloma
    • DeepTag-GPRC5D Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Oct 10, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia With Failed Remission
    • São Paulo, SP, Brazil
      Instituto do Cancer do Estado de Sao Paulo
    Sep 12, 2023

    Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

    Not yet recruiting
    • Refractory Multiple Myeloma
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Nov 17, 2023

    Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Changchun, China
    • +5 more
    Jan 27, 2023

    Learn How Triple Class Refractory Multiple Myeloma Are Treated

    Not yet recruiting
    • Relapse Multiple Myeloma
    • Refractory Multiple Myeloma
      • (no location specified)
      Feb 15, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Jun 8, 2023

      T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

      Withdrawn
      • T-cell Acute Lymphoblastic Leukemia
      • T-lymphoblastic Lymphoma
      • Target CD7 CAR-T cells
      • Kunming, Yunnan, China
        920th Hospital of Joint Logistics Support Force of People's Libe
      Nov 23, 2022

      Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

      Not yet recruiting
      • Multiple Myeloma
      • Multiple Myeloma in Relapse
      • Belantamab mafodotin, Venetoclax
      • (no location specified)
      May 10, 2023

      Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

      Recruiting
      • Acute Myeloid Leukemia
      • +3 more
      • CD123 targeted CAR-NK cells
      • Taiyuan, Shanxi, China
        Shanxi Bethune Hospital
      Aug 28, 2023

      Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

      Not yet recruiting
      • Hemophagocytic Lymphohistiocytosis
      • L-DEP and PD-1 antibody
      • Beijing, China
        Beijing Friendship Hospital, Capital Medical University
      Apr 19, 2022

      ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)

      Not yet recruiting
      • ALL, Childhood B-Cell
      • +2 more
      • Tafasitamab
      • (no location specified)
      Nov 25, 2022

      Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

      Recruiting
      • Relapsed and/or Refractory Multiple Myeloma
      • Plasma Cell Leukemia in Relapse
      • Biological
      • Shanghai, Shanghai, China
        Shanghai Tongji Hospital
      May 29, 2023

      Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

      Recruiting
      • Multiple Myeloma in Relapse
      • Aurora, Colorado
        University of Colorado Hospital
      Jan 31, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

      Active, not recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • Poitiers, France
        CHU Poitiers
      Jan 9, 2023

      CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)

      Recruiting
      • CD19+ Relapse/Refractory B-ALL
      • CAR-T-19 Cells
      • Beijing, Beijing, China
        Chinese PLA General Hospital
      Feb 26, 2022